Improving head and neck sarcoma care: The impact of a specialized multidisciplinary team approach on diagnosis and patient outcomes.

Autor: Tatsis D; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK. Electronic address: dimitris.tatsis@nhs.net., Sinha D; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK., Le Grange F; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK., Jay A; University College London Hospitals NHS Trust, London, UK., Salli M; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK., Sadeghian G; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK., Morley S; University College London Hospitals NHS Trust, London, UK., Wan S; University College London Hospitals NHS Trust, London, UK., Karavasilis V; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK., Windsor R; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK., Strauss SJ; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK., Kalavrezos N; London Sarcoma Service, University College London Hospitals NHS Trust, London, UK.
Jazyk: angličtina
Zdroj: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2024 Sep; Vol. 50 (9), pp. 108531. Date of Electronic Publication: 2024 Jul 03.
DOI: 10.1016/j.ejso.2024.108531
Abstrakt: Objective: Globally, head & neck sarcoma care pathways remain unclear. In 2018, the London Sarcoma Service (LSS) set up a dedicated head and neck sarcoma (HNS) multidisciplinary team (MDT) with a clear objective to provide formal access to super-specialist expertise in diagnosis, treatment planning and management of HNS. The aim of the study is to provide first results of a dedicated HNS MDT.
Methods: All patients discussed between 2018 and 2022, in HNS MDT, with a new histologically confirmed HNS diagnosis were included in the study. Demographics, anatomic site, morphology, MDT recommendation, treatment details and outcomes were obtained from electronic patient records.
Results: A total of 337 patients were discussed in the HNS MDT of which 178 patients were included in the study, with a median age of 53 years(range 2-94); 67 % were soft tissue sarcomas(STS) and 33 % were bone sarcomas(BS), of which 43 % and 71 % were high grade, respectively. 55 % BS and 39 % STS underwent surgery. 9 % of BS and 7 % of STS received adjuvant Proton Beam therapy. With a median follow-up of 2.16 years, recurrence was observed in 12 %, distant metastasis in 6 % of patients and overall survival was 72 %.
Conclusion: The HNS MDT provides expertise on diagnosis and multi-modality management of HNS. STS are more likely to be misdiagnosed. Atypical imaging characteristics should trigger a specialist referral. Adequate surgery at first presentation remains the mainstay of treatment and the strongest prognosticator of overall survival. Formation of an expert working group specific to HNS must work towards streamlining sarcoma care.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: